1. Evaluación del tratamiento de osteoporosis con determinación urinaria de desoxipiridinolina en mujeres posmenopáusicas.
- Author
-
Solís-Cabrera, Bella Herlinda, Ramírez-Benítez, María del Carmen, Yolanda, Cocotle-Ronzón, Magdalena, Moreno-Todd, and Abraham Heriberto, Soto-Cid
- Subjects
- *
OSTEOPENIA , *OSTEOPOROSIS , *DENSITOMETRY , *STATISTICS , *QUALITY of life , *PATIENTS , *THERAPEUTICS - Abstract
Objective: to evaluate urinary desoxypiridinoline (Dpd) levels in postmenopause patients, with osteoporosis or osteopenia after treatment with sodium alendronate. Methods: a quasiexperimental study was carried out in 118 patients, aged from 41 to 69 years. According to the densitometry results and treatment received, we formed five groups: group I, patients with osteoporosis, treated with 10 mg/day of alendronate; group IIA, patients with osteopenia treated with alendronate 5 mg/day; group IIB, patients with osteopenia treated with hormonal therapy replacement (HTR); group IIIA, patients with normal densitometry treated with change of life style habits; and group IIIB, patients with normal densitometry treated with HTR. Dpd urinary levels were measured in all patients at the beginning and 60 days after. The statistical analysis was t Student paired. Results: the group I diminished 7.8 nmol Dpd/mmol Cr with a p = 0.001. In the other groups the reduction of the urinary Dpd level was not significant. Conclusions: in osteoporosis the urinary Dpd excretion diminishes after 60 days of treatment with 10 mg/day of sodium alendronate. [ABSTRACT FROM AUTHOR]
- Published
- 2009